Cognigenics is pioneering advancements in RNA-based therapeutics aimed at transforming the treatment landscape for mental health and neurocognitive disorders. Their innovative approach utilizes genetic neuroengineering techniques to noninvasively target neural networks associated with conditions such as anxiety, depression, and cognitive decline. By employing short hairpin RNA (shRNA)-based therapeutics, Cognigenics aims to alleviate the detrimental effects of chronic stress and neural dysregulation, addressing disorders like Anxiety Spectrum Disorders (ASD), Mild Cognitive Impairment (MCI), and Alzheimer’s Disease (AD). Their therapies are designed to enhance cognitive functions, including focus and mental clarity, while promoting relaxation and optimism, all with a focus on molecular precision to tackle specific pathophysiological issues.

The company distinguishes itself from traditional pharmaceutical approaches, which often rely on broad-spectrum medications with significant side effects. Cognigenics' technology offers high precision in targeting neuronal receptors, resulting in potentially higher efficacy rates and improved patient tolerance. Their preclinical studies indicate that their RNA-based interventions may outperform standard treatments, with the added benefit of requiring only a single dose for long-term effectiveness, contrasting sharply with the daily medication regimens typical of existing therapies. This innovative model not only aims to enhance patient compliance but also seeks to significantly reduce the burden of mental health disorders through a more effective and safer therapeutic approach.

United States

Cognigenics develops innovative RNA-based gene therapies targeting memory loss, cognitive decline, anxiety associated with mild cognitive impairment and other neurocognitive and neuropsychiatric disorders. Our intranasal delivery platform targets neuronal receptors in the brain involved in CNS disorders including anxiety, and Mild Cognitive Impairment.

Cognigenics

Company Details